Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-In-Human (FIH) Study of Inhibitory Interneurons (NRTX- 1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

Next Previous
X
Search
Trial Profile

A First-In-Human (FIH) Study of Inhibitory Interneurons (NRTX- 1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NRTX-1001 (Primary)
  • Indications Partial epilepsies; Seizures; Temporal-lobe-epilepsy
  • Focus Adverse reactions; First in man
  • Sponsors Neurona Therapeutics

    • Most Recent Events

    • 18 Jun 2024 According to a Neurona Therapeutics media release, company announced that the U.S Food and Drug Administration (FDA) has granted the company's lead product candidate, NRTX-1001,the RMAT expedited program designation for drug-resistant mesial temporal lobe epilepsy (MTLE).
    • 15 Apr 2024 According to a Neurona Therapeutics media release, enrollment is currently underway at epilepsy centers across the United States.
    • 15 Apr 2024 According to a Neurona Therapeutics media release, data from the study was presented at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, CO.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top